Allogene Announces $175 Mln Public Offering

April 14, 2026 — 02:08 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, on Monday, announced a proposed underwritten public offering of $175 million in shares of the company's common stock.

The proceeds from the public offering are expected to be used for general corporate purposes, clinical trial expenses, research and development, general and administrative expenses, and capital expenditure.

The company is currently developing allogenic CAR-T (Allo CAR T) therapies to treat autoimmune and cancer indications, including lymphoma, small cell lung cancer (SCLC), gastric and pancreatic cancers.

Additionally, Allogene is offering underwriters a 30-day option to purchase up to $26.25 million in shares.

ALLO closed Monday at $3.06, up 12.50%. In the overnight trade, shares were at $2.93, down 4.25%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Allogene Announces $175 Mln Public Offering

Tags

Latest Articles